Cristine E Berry1, M Bradley Drummond1, MeiLan K Han2, Daner Li3, Cathy Fuller3, Andrew H Limper4, Fernando J Martinez2, Marvin I Schwarz5, Frank C Sciurba6, Robert A Wise7. 1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI. 3. C-TASC Clinical Trials and Surveys Corporation, Owings Mills, MD. 4. Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN. 5. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver School of Medicine, Aurora, CO. 6. Division of Pulmonary and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 7. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: rwise@jhmi.edu.
Abstract
BACKGROUND: Health-related quality-of-life (HRQL) measures have been correlated with lung function in patients with COPD and interstitial lung disease (ILD). However, different pathophysiologic mechanisms may influence how these distinct diseases affect HRQL, resulting in differing HRQL by pulmonary diagnosis among patients with similar severity of ventilatory impairment. METHODS: The National Heart, Lung, and Blood Institute Lung Tissue Research Consortium provided data on well-characterized participants with COPD (n = 576) and ILD (n = 405) at four clinical sites. Using multiple linear regression, we examined the effects of FEV₁ (% predicted) and diagnosis (ILD vs COPD) on HRQL scores, including total St. George Respiratory Questionnaire (SGRQ) scores and Short Form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. RESULTS: Participants with ILD had, on average, higher SGRQ scores (15.33 points; 95% CI, 12.46-18.19; P <.001) and lower SF-12 PCS scores (-4.73 points; 95% CI, -6.31 to -3.14; P <.001) compared with patients with COPD with similar FEV₁ % predicted values, indicating worse HRQL. The specific diagnosis also modified the effect of FEV₁ on the total SGRQ score (P = .003) and the SF-12 PCS score (P = .03). There was no relationship between lung function and SF-12 MCS scores. CONCLUSIONS: HRQL scores were worse for patients with ILD compared with patients with COPD with similar degrees of ventilatory impairment. Differences in dyspnea mechanism or in the rate of disease progression may account for these differences in HRQL.
BACKGROUND: Health-related quality-of-life (HRQL) measures have been correlated with lung function in patients with COPD and interstitial lung disease (ILD). However, different pathophysiologic mechanisms may influence how these distinct diseases affect HRQL, resulting in differing HRQL by pulmonary diagnosis among patients with similar severity of ventilatory impairment. METHODS: The National Heart, Lung, and Blood Institute Lung Tissue Research Consortium provided data on well-characterized participants with COPD (n = 576) and ILD (n = 405) at four clinical sites. Using multiple linear regression, we examined the effects of FEV₁ (% predicted) and diagnosis (ILD vs COPD) on HRQL scores, including total St. George Respiratory Questionnaire (SGRQ) scores and Short Form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. RESULTS:Participants with ILD had, on average, higher SGRQ scores (15.33 points; 95% CI, 12.46-18.19; P <.001) and lower SF-12 PCS scores (-4.73 points; 95% CI, -6.31 to -3.14; P <.001) compared with patients with COPD with similar FEV₁ % predicted values, indicating worse HRQL. The specific diagnosis also modified the effect of FEV₁ on the total SGRQ score (P = .003) and the SF-12 PCS score (P = .03). There was no relationship between lung function and SF-12 MCS scores. CONCLUSIONS: HRQL scores were worse for patients with ILD compared with patients with COPD with similar degrees of ventilatory impairment. Differences in dyspnea mechanism or in the rate of disease progression may account for these differences in HRQL.
Authors: Eanes Delgado Barros Pereira; Renata Pinto; Marcelo Alcantara; Marta Medeiros; Rosa Maria Salani Mota Journal: J Bras Pneumol Date: 2009-08 Impact factor: 2.624
Authors: Jeffrey J Swigris; Kevin K Brown; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Frederick S Wamboldt Journal: Respir Med Date: 2009-10-07 Impact factor: 3.415
Authors: MeiLan K Han; Jeffrey Swigris; Lyrica Liu; Brian Bartholmai; Susan Murray; Nicholas Giardino; Bruce Thompson; Margaret Frederick; Daner Li; Marvin Schwarz; Andrew Limper; Kevin Flaherty; Fernando J Martinez Journal: Respir Med Date: 2009-12-24 Impact factor: 3.415
Authors: Cristine E Berry; Meilan K Han; Bruce Thompson; Andrew H Limper; Fernando J Martinez; Marvin I Schwarz; Frank C Sciurba; Gerald J Criner; Robert A Wise Journal: Ann Am Thorac Soc Date: 2015-01
Authors: Laurie A Hohberger; Darrell R Schroeder; Brian J Bartholmai; Ping Yang; Christine H Wendt; Peter B Bitterman; Ola Larsson; Andrew H Limper Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Rachida Rafiq; Floor E Aleva; Jasmijn A Schrumpf; Yvonne F Heijdra; Christian Taube; Johannes Ma Daniels; Paul Lips; Pierre M Bet; Pieter S Hiemstra; André Jam van der Ven; Martin den Heijer; Renate T de Jongh Journal: BMC Pulm Med Date: 2015-09-23 Impact factor: 3.317
Authors: Boglárka Lilla Szentes; Michael Kreuter; Thomas Bahmer; Surinder S Birring; Martin Claussen; Julia Waelscher; Reiner Leidl; Larissa Schwarzkopf Journal: Respir Res Date: 2018-05-25
Authors: Yuhan Wen; Dongming Wang; Min Zhou; Yun Zhou; Yanjun Guo; Weihong Chen Journal: Int J Environ Res Public Health Date: 2019-01-17 Impact factor: 3.390
Authors: Sarath Raju; Meredith C McCormack; Michael Bradley Drummond; Hema C Ramamurthi; Christian A Merlo; Robert A Wise; Shruti H Mehta; Robert H Brown; Gregory D Kirk Journal: J Acquir Immune Defic Syndr Date: 2020-10-01 Impact factor: 3.771